RCM
XBI icon

RA Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

RA Capital Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,228,240
Closed -$111M – 99
2024
Q4 		$111M Buy
+1,228,240
New +$119M 1.47% 19

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

RA Capital Management's XBI Position: Q1 2025 in Review

RA Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 1,228,240 shares — an estimated $111M sold.

RA Capital Management first reported a position in XBI in Q4 2024 and held it in 1 quarter. The position peaked at $111M in Q4 2024. 683 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

  • RA Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
  • RA Capital Management sold 1,228,240 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $111M.
  • RA Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and held it in 1 quarter.
  • RA Capital Management's State Street SPDR S&P Biotech ETF position peaked at $111M in Q4 2024.
  • 683 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on RA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.